Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220759 · ClinicalTrials.gov registry record · Phase 3
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT07220759 is a Phase 3 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 330 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07220759, a Phase 3 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
Conditions Studied
Interventions
- DRUG Cagrilintide
- DRUG Placebo (matched to Cagrilintide)
Study Locations (20)
Florida
- Walgreens - Store 4442 - Kissimmee
- Optimal Research Sites - Orange City
- Center for Diab,Obes & Metab - Pembroke Pines
- Palm Beach Research Center - West Palm Beach
California
- Scripps Whittier Diabetes Inst - La Jolla
- Clinical Trials Research - Lincoln
- Pacific Clinical Studies - Los Alamitos
Alabama
- Univ of Alabama_Birmingham - Birmingham
- Chambliss Clinical Trials, LLC - Montgomery
North Carolina
- Centricity Res New Bern Multispeciality - New Bern
- Accellacare - Wilmington
Arizona
- Elite Clinical Network - Tucson - Tucson
Hawaii
- East West Med Res Inst - Honolulu
Indiana
- MediSphere Medical RC - Evansville
Nevada
- Walgreens - Store 3915 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220759
The ClinicalTrials.gov registry entry for NCT07220759 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (60% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Cagrilintide is the first listed.
NCT07220759 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07220759 about?
NCT07220759 is a clinical study titled "Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide". This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment particip...
What is the current status of trial NCT07220759?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2025-11-05. Estimated completion is 2027-06-30.
What conditions does trial NCT07220759 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.
What interventions are being tested in trial NCT07220759?
The interventions under investigation include: Cagrilintide (DRUG), Placebo (matched to Cagrilintide) (DRUG).
Who is sponsoring clinical trial NCT07220759?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220759 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.